ecogacrinnews2

April 15, 2022

Trial Spotlight: Nadine Tung on the EA1181/CompassHER2 pCR Trial for HER2-Positive Breast Cancer

This study aims to determine if it is safe to omit adjuvant chemotherapy after surgery for patients with pathologic complete response (pCR) after 12 weeks of pre-operative treatment
April 15, 2022

News in Brief, April 2022

Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
February 24, 2022

From the Co-Chairs, February 2022

Reflections on the 50th Anniversary of the National Cancer Act of 1971
February 24, 2022

Now Enrolling: EA2205 for a Rare Form of Liver Cancer

ECOG-ACRIN is leading the first randomized trial evaluating treatment strategies for patients with combined hepatocellular carcinoma-cholangiocarcinoma
February 24, 2022

Edith Mitchell Reflects on Equity Initiatives at ECOG-ACRIN

On the occasion of Black History Month, ECOG-ACRIN speaks with Edith Mitchell, MD about health equity and diversity initiatives within the Group
February 24, 2022

ECOG-ACRIN Sarcoma Working Group Builds Steam in Second Year

Kenneth Cardona, MD, FACS, of the Winship Cancer Institute at Emory University, discusses the Sarcoma Working Group’s progress to date and outlines future plans
February 24, 2022

Trial Spotlight: Nataliya Uboha on the EA2183 Trial for Esophageal and Gastric Adenocarcinoma

This randomized phase III trial explores the addition of radiotherapy to the usual treatment (chemotherapy) in patients with esophagus and stomach cancer with limited spread
February 24, 2022

News in Brief, February 2022

Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
January 26, 2022

Come Again? Communicating Clearly About Risk of Recurrence After Early-Stage Breast Cancer

Mary Lou Smith and colleagues at the Research Advocacy Network recently explored how well patients with early-stage breast cancer understand risk of recurrence
January 26, 2022

Trial Spotlight: Jarushka Naidoo on the EAQ172 Trial for Steroid-Refractory Pneumonitis

This randomized phase II trial aims to establish which agent, infliximab versus intravenous immunoglobulin, may lead to greatest benefit as pneumonitis treatment for patients receiving PD-1/PD-L1 therapy
December 22, 2021

Trial Spotlight: Helena Yu on the EA5182 Trial for Metastatic, EGFR-Mutant Non-Small Cell Lung Cancer

This trial aims to help define the optimal first-line treatment for patients with advanced, EGFR-mutant NSCLC and elucidate mechanisms of resistance to therapy
October 19, 2021

From the Co-Chairs, October 2021

A focus on the Fall 2021 ECOG-ACRIN Group Meeting; remembering two major leaders in oncology; studying smoking cessation in patients with cancer